Candela Corporation (NASDAQ: CLZR) announced today that Health Canada has cleared the new QuadraLASE� advanced CO2 fractional laser for distribution in Canada. Launched at the American Academy of Dermatology Annual Meeting in March 2009, the QuadraLASE is changing the way practitioners are looking at fractional CO2 laser treatments. With a unique combination of the proven performance of a CO2 laser and an innovative scanning device, the QuadraLASE is an effective solution for popular aesthetic treatments such as skin rejuvenation*, skin tightening/wrinkle reduction**, uneven tone and texture, and acne scarring.

President and CEO, Gerard E. Puorro, commented, �Candela�s customers in the United States, Europe and Australia are looking at fractional CO2 in a new way and embracing the QuadraLASE as a total rejuvenation system. In addition, they are reporting that the QuadraLASE is a great option for patients who want fast results and better looking skin without the need for multiple treatments.�

Mr. Puorro added, �We are excited that the expansion of the QuadraLASE into Canada means that practitioners will have more choices and greater flexibility to meet their individual practice needs. Numerous physicians that have used other fractional technologies have reported that they are very satisfied with the results that they are getting with the QuadraLASE without the cost of consumables.�

Mr. Puorro continued, �Additionally, our customers in other parts of the world are finding that the QuadraLASE is the ideal complement to our lasers including the AlexTriVantage�, our multi-wavelength Q-switched laser, and the Vbeam� Perfecta for best-in-class, anti-aging treatments.�

About QuadraLASE:

The new QuadraLASE fractional laser features proprietary QuadraSCAN� technology, which reduces heat build-up in the skin, resulting in increased patient comfort. Candela QuadraLASE offers performance, versatility and value in a fractional CO2 laser. In addition, the system is engineered to fit the needs of every aesthetic practice offering:

  • Value with no disposables � keeping long term operating costs down.
  • Choice of QS 300 micron and QD 180 micron handpieces, providing true variable depth ablation.
  • Elegant design and small footprint minimizing the need for space.
  • Renowned Candela after-the-sale support.

For more information please visit www.quadralase.com or call 800-733-8550 ext. 247.

* Skin rejuvenation by reduction of diffuse redness and pigmentation.

** Skin tightening through wrinkle reduction.

QuadraLASE and QuadraSCAN are trademarks, and Candela is a registered trademark of Candela Corporation.

About CANDELA: Candela Corporation manufactures and distributes innovative clinical solutions that enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical conditions using lasers, aesthetic laser systems, and other advanced technologies. Founded near Boston in 1970, Candela markets and services its products in 86 countries from offices and distributors in the United States, Europe, Japan, China and other Asian locations. Candela established the aesthetic laser market 20 years ago, and currently has an installed base of over 14,000 systems worldwide. Visit Candela on the Web at http://www.candelalaser.com.

Safe Harbor Statement: Except for the historical information contained herein, this news release contains forward-looking statements that constitute Candela Corporation�s current intentions, hopes, beliefs, expectations or predictions of the future, which are therefore inherently subject to risks and uncertainties. These statements include declarations regarding our or our management�s beliefs and current expectations. In some cases, you can identify forward-looking statements by terminology such as �may,� �will,� �should,� �expects,� �plans,� �anticipates,� �believes,� �estimates,� �predicts,� �potential� or �continue� or the negative of such terms or other comparable terminology. These forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. The risks and uncertainties that may affect forward-looking statements include, among others: the availability of, and our ability to successfully implement strategic and operational alternatives, the pendency of re-examinations of the �844 Patent and the �568 Patent before the PTO, our alleged infringement of the �844 Patent and the �568 Patent, the validity of the �844 Patent and the �568 Patent, our expected legal expenses, our exploration of strategic and operational alternatives, the expected recovery of our industry, our future revenue, gross margin, expense levels and earnings, our growth prospects, market acceptance of our products, the strength of our distribution channels, our ability to add new products, our ability to expand regulatory approvals and the liquidity of our common stock, the cancellation or deferral of customer orders, the risk of a material adverse judgment or increased litigation-related expenses in pending litigation matters, dependence on a small number of strategic distribution relationships, difficulties in the timely development and market acceptance of new products, unanticipated increases in expenses, market developments that vary from the current public expectations concerning the growth of the laser industry, increased competitive pressures, changes in economic conditions, or difficulties in obtaining timely regulatory approvals. Further information on factors that could affect Candela's performance is included in Candela's periodic reports filed with the SEC. Candela cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Candela expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Candela's expectations or any change in events, conditions or circumstances on which any such statement is based.

Candela (MM) (NASDAQ:CLZR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Candela (MM).
Candela (MM) (NASDAQ:CLZR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Candela (MM).